EXCLUSIVE: Plus Therapeutics Tells Benzinga 'FDA approves continuation to Phase 1 Part B of the ReSPECT-LM clinical trial'
Portfolio Pulse from Benzinga Newsdesk
Plus Therapeutics has received approval from the FDA to continue to Phase 1 Part B of the ReSPECT-LM clinical trial.
August 11, 2023 | 10:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Plus Therapeutics' stock may see positive movement as the FDA has approved the continuation to Phase 1 Part B of the ReSPECT-LM clinical trial.
The FDA's approval for the continuation of the clinical trial is a positive development for Plus Therapeutics. This could lead to increased investor confidence and a potential rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100